Principal Financial Group Inc. increased its position in Xylem Inc. (NYSE:XYL) by 0.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 271,852 shares of the company’s stock after buying an additional 677 shares during the period. Principal Financial Group Inc. owned about 0.15% of Xylem worth $12,138,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Glenmede Trust Co. NA boosted its position in shares of Xylem by 9.4% in the second quarter. Glenmede Trust Co. NA now owns 2,908 shares of the company’s stock worth $129,000 after buying an additional 250 shares during the period. Evercore Wealth Management LLC boosted its position in shares of Xylem by 6.3% in the second quarter. Evercore Wealth Management LLC now owns 3,315 shares of the company’s stock worth $148,000 after buying an additional 195 shares during the period. Invictus RG bought a new position in shares of Xylem during the first quarter worth approximately $142,000. Signature Estate & Investment Advisors LLC bought a new position in shares of Xylem during the second quarter worth approximately $162,000. Finally, BlueMountain Capital Management LLC bought a new position in shares of Xylem during the first quarter worth approximately $180,000. 84.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of Xylem Inc. (NYSE:XYL) opened at 49.70 on Wednesday. The company has a market capitalization of $8.91 billion, a P/E ratio of 26.53 and a beta of 1.15. Xylem Inc. has a 12-month low of $31.67 and a 12-month high of $53.25. The firm has a 50-day moving average price of $50.98 and a 200 day moving average price of $46.34.
Xylem (NYSE:XYL) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.01. The firm earned $932 million during the quarter, compared to analysts’ expectations of $927.69 million. Xylem had a return on equity of 16.41% and a net margin of 9.22%. The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.43 EPS. On average, equities research analysts predict that Xylem Inc. will post $2.04 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 21st. Stockholders of record on Wednesday, August 31st were given a $0.1549 dividend. The ex-dividend date was Monday, August 29th. This represents a $0.62 dividend on an annualized basis and a dividend yield of 1.25%. Xylem’s payout ratio is 33.16%.
XYL has been the topic of several research analyst reports. RBC Capital Markets set a $51.00 target price on Xylem and gave the company a “buy” rating in a research note on Tuesday, August 16th. Barclays PLC boosted their target price on Xylem from $39.00 to $45.00 and gave the company an “equal weight” rating in a research note on Monday, July 18th. Canaccord Genuity reissued a “hold” rating and set a $50.00 target price (up from $45.00) on shares of Xylem in a research note on Tuesday, August 16th. Zacks Investment Research cut Xylem from a “buy” rating to a “hold” rating in a research note on Friday, July 15th. Finally, Royal Bank Of Canada boosted their target price on Xylem from $47.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $45.00.
In other Xylem news, Director Steven R. Loranger sold 33,887 shares of Xylem stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $48.11, for a total transaction of $1,630,303.57. Following the completion of the sale, the director now owns 11,243 shares of the company’s stock, valued at approximately $540,900.73. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steven R. Loranger sold 32,246 shares of Xylem stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $48.01, for a total value of $1,548,130.46. Following the sale, the director now directly owns 38,334 shares of the company’s stock, valued at approximately $1,840,415.34. The disclosure for this sale can be found here. 0.77% of the stock is owned by insiders.
Xylem Inc is engaged in the design, manufacturing, and application of engineered technologies for the water industry. The Company is an equipment and service provider for water and wastewater applications with a portfolio of products and services addressing the cycle of water, from collection, distribution and use to the return of water to the environment.
Receive News & Ratings for Xylem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.